188 related articles for article (PubMed ID: 36162702)
21. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.
Buckarma EH; Werneburg NW; Conboy CB; Kabashima A; O'Brien DR; Wang C; Ilyas SI; Smoot RL
Mol Cancer Res; 2020 Oct; 18(10):1574-1588. PubMed ID: 32646966
[TBL] [Abstract][Full Text] [Related]
22. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells.
Oeurn K; Jusakul A; Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Kongpetch S
In Vivo; 2023; 37(4):1628-1637. PubMed ID: 37369494
[TBL] [Abstract][Full Text] [Related]
23. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
[TBL] [Abstract][Full Text] [Related]
24. Deregulation of Hippo kinase signalling in human hepatic malignancies.
Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
26. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
28. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.
Chen MH; Yen CC; Cheng CT; Wu RC; Huang SC; Yu CS; Chung YH; Liu CY; Chang PM; Chao Y; Chen MH; Chen YF; Chiang KC; Yeh TS; Chen TC; Huang CY; Yeh CN
Oncotarget; 2015 Sep; 6(27):23594-608. PubMed ID: 26090720
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
[TBL] [Abstract][Full Text] [Related]
30. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
[TBL] [Abstract][Full Text] [Related]
31. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
Moriyama K; Hori T
Int J Hematol; 2019 Nov; 110(5):591-598. PubMed ID: 31428968
[TBL] [Abstract][Full Text] [Related]
33. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
34. [The combination of YAP/TAZ predicts the clinical prognosis in patients with cholangiocarcinoma after radical resection].
Liu Y; Wu Y; Ouyang YS; He JJ; Shen LL; Qi H; Cao F; Chen SG
Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):637-643. PubMed ID: 34619841
[No Abstract] [Full Text] [Related]
35. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
[TBL] [Abstract][Full Text] [Related]
36. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells.
Fingas CD; Bronk SF; Werneburg NW; Mott JL; Guicciardi ME; Cazanave SC; Mertens JC; Sirica AE; Gores GJ
Hepatology; 2011 Dec; 54(6):2076-88. PubMed ID: 22038837
[TBL] [Abstract][Full Text] [Related]
37.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
38. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
[TBL] [Abstract][Full Text] [Related]
39. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
40. The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S; Kleinhenz F; Shevchenko E; Stahl A; Rasen Y; Geisler C; Ruhm K; Klaumuenzer M; Kronenberger T; Laufer SA; Sundberg-Malek H; Bui KC; Horger M; Biskup S; Schulze-Osthoff K; Templin M; Malek NP; Poso A; Bitzer M
Nat Commun; 2024 Feb; 15(1):1287. PubMed ID: 38346946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]